Gynecologic Cancer

Official Title: A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Study Purpose: To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.

Status: Recruiting

Official Title: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Study Purpose: To compare progression-free survival after platinum-based chemotherapy (doublet) plus bevacizumab and randomized to maintenance mirvetuxemab sorvtansine (MIRV) plus bevacizumab (Arm 1) versus bevacizumab alone (Arm 2)

Status: Recruiting

Official Title: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

Study Purpose: To investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Status: Recruiting

Official Title: A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, Serabelisib with Paclitaxel, and Paclitaxel Alone in Patients with Advanced or Recurrent Endometrial Cancer

Study Purpose: To determine whether the combination of investigational drugs called sapanisertib and serabelisib with paclitaxel, or just serabelisib with paclitaxel works better at treating endometrial cancer when compared to using paclitaxel alone.

Status: Pending

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research

Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.

Status: Recruiting

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Study Purpose: To determine how well the oral drug Letrozole works with or without Paclitaxel and Carboplatin in treating stage II-IV low grade cancer of the ovary or peritoneum.

Status: Recruiting

Official Title: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial

Study Purpose: To investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis and/or extracapsular extension in the SN.

Status: Recruiting

Official Title: Testing the addition of Herceptin Hylecta or Phesgo to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma.

Study Purpose: To determine if the addition of the study drugs will lower the chance of this disease from coming back.

Status: Recruiting

Official Title: A PHASE II STUDY OF ANDROGEN RECEPTOR (AR) INHIBITION BY DAROLUTAMIDE IN COMBINATION WITH LEUPROLIDE ACETATE AND EXEMESTANE IN RECURRENT ADULT-TYPE OVARIAN GRANULOSA CELL TUMOR

Study Purpose: To test the effectiveness and the good and bad effects of the drug darolutamide in combination with leuprolide acetate and exemestane 

Status: Suspended